The National Institute for Health and Care Excellence (NICE) has issued a provisional recommendation stating that Leqembi (lecanemab), a new drug designed to slow the progression of early Alzheimer's disease, is currently too costly for routine use within the NHS. This decision means that patients in England will not have access to the treatment, despite its recent approval by the Medicines and Healthcare products Regulatory Agency (MHRA) earlier this year.
Leqembi, developed by Japanese pharmaceutical company Eisai, has shown in clinical trials to slow cognitive decline in individuals with early-stage Alzheimer's disease. While it does not cure the condition, it offers a new approach to managing symptoms and potentially extending the period of independent living for patients. The drug is administered via intravenous infusion every two weeks and targets amyloid plaques in the brain, which are a hallmark of Alzheimer's.
NICE’s evaluation highlighted concerns regarding the drug's cost-effectiveness, particularly in relation to its price tag. The organisation acknowledged Leqembi's clinical effectiveness but concluded that, at its current price, it does not offer sufficient value for money to justify its inclusion in NHS budgets. This assessment is crucial for ensuring that NHS resources are allocated efficiently across a wide range of health needs.
The decision has significant implications for an estimated 140,000 people in the UK who are living with early Alzheimer's disease and could potentially benefit from such a treatment. Alzheimer's disease affects around 900,000 people in the UK, with the majority being over 65. The lack of accessible disease-modifying treatments has long been a frustration for patients and their families, making this provisional rejection a setback for many.
NICE has indicated that it is open to further discussions with Eisai to explore a potential price reduction that would make the drug more affordable and therefore viable for NHS funding. The manufacturer now has the opportunity to appeal this provisional decision or submit a revised proposal. A final decision on Leqembi's availability on the NHS is expected following this consultation period and any subsequent negotiations.
Patients concerned about their memory or cognitive health should always consult their GP. For urgent medical advice, individuals can call NHS 111.
Source: Pulse Today